Autologous bone marrow transplantation in primary breast cancer

The American experience

W. P. Peters, J. W. Fay, H. K. Holland, T. Ahmed, B. J. Bolwell, J. Wolf, L. Damon, G. Long, Lee Schwartzberg, S. L. Goldberg, D. J. Friedman, J. P. Lynch, B. B. Weinberger, R. F. Taylor, E. Stadtmauer, R. M. Rifkin, E. R. Broun, P. L. McCarthy, K. Zamkoff

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

The use of high-dose chemotherapy with bone marrow transplantation is becoming easier to administer because of improved supportive care techniques and is being increasingly utilized for patients with high-risk primary breast cancer. We report here survey data from 33 medical centers in the United States using this therapeutic approach in 662 patients outside of the cooperative group sponsored randomized clinical trials between 1987 and 1993. Centers provided patient specific data on pretreatment characteristics, therapy and supportive care used, and disease outcome and toxicity data for each patient. Seventy-four percent of the patients were treated by 11 (33%) of the centers; 15 institutions had treated fewer than 10 patients. The median number of lymph nodes involved was 13; the majority of patients (51%) had T2 lesions and 28% of tumors measured more than 5 cm. The most common induction chemotherapy regimens were CAF or AFM, and 72% of patients received one of three transplant preparative regimens. Overall survival at 3 years was 79% (95% CI: 71%-85%) with event-free survival at three years of 69% (95% CI: 61%-76%). Patients with hormone-receptor positive tumors had a event-free (p = 0.02) and overall survival (p = 0.01) that was significantly greater than patients with hormone receptor negative tumors. High-dose chemotherapy with autologous cellular support as consolidation in patients with high-risk primary breast cancer produces event-free and overall survival which appears superior to historical and contemporary data in this setting using standard-dose chemotherapy.

Original languageEnglish (US)
JournalBone Marrow Transplantation
Volume15
Issue numberSUPPL. 1
StatePublished - Jan 1 1995
Externally publishedYes

Fingerprint

Autologous Transplantation
Bone Marrow Transplantation
Breast Neoplasms
Drug Therapy
Disease-Free Survival
Hormones
Neoplasms
Induction Chemotherapy
Survival
Randomized Controlled Trials
Lymph Nodes
Transplants

All Science Journal Classification (ASJC) codes

  • Hematology
  • Transplantation

Cite this

Peters, W. P., Fay, J. W., Holland, H. K., Ahmed, T., Bolwell, B. J., Wolf, J., ... Zamkoff, K. (1995). Autologous bone marrow transplantation in primary breast cancer: The American experience. Bone Marrow Transplantation, 15(SUPPL. 1).

Autologous bone marrow transplantation in primary breast cancer : The American experience. / Peters, W. P.; Fay, J. W.; Holland, H. K.; Ahmed, T.; Bolwell, B. J.; Wolf, J.; Damon, L.; Long, G.; Schwartzberg, Lee; Goldberg, S. L.; Friedman, D. J.; Lynch, J. P.; Weinberger, B. B.; Taylor, R. F.; Stadtmauer, E.; Rifkin, R. M.; Broun, E. R.; McCarthy, P. L.; Zamkoff, K.

In: Bone Marrow Transplantation, Vol. 15, No. SUPPL. 1, 01.01.1995.

Research output: Contribution to journalArticle

Peters, WP, Fay, JW, Holland, HK, Ahmed, T, Bolwell, BJ, Wolf, J, Damon, L, Long, G, Schwartzberg, L, Goldberg, SL, Friedman, DJ, Lynch, JP, Weinberger, BB, Taylor, RF, Stadtmauer, E, Rifkin, RM, Broun, ER, McCarthy, PL & Zamkoff, K 1995, 'Autologous bone marrow transplantation in primary breast cancer: The American experience', Bone Marrow Transplantation, vol. 15, no. SUPPL. 1.
Peters WP, Fay JW, Holland HK, Ahmed T, Bolwell BJ, Wolf J et al. Autologous bone marrow transplantation in primary breast cancer: The American experience. Bone Marrow Transplantation. 1995 Jan 1;15(SUPPL. 1).
Peters, W. P. ; Fay, J. W. ; Holland, H. K. ; Ahmed, T. ; Bolwell, B. J. ; Wolf, J. ; Damon, L. ; Long, G. ; Schwartzberg, Lee ; Goldberg, S. L. ; Friedman, D. J. ; Lynch, J. P. ; Weinberger, B. B. ; Taylor, R. F. ; Stadtmauer, E. ; Rifkin, R. M. ; Broun, E. R. ; McCarthy, P. L. ; Zamkoff, K. / Autologous bone marrow transplantation in primary breast cancer : The American experience. In: Bone Marrow Transplantation. 1995 ; Vol. 15, No. SUPPL. 1.
@article{6cc7546b590841eeafc079caa9a406d5,
title = "Autologous bone marrow transplantation in primary breast cancer: The American experience",
abstract = "The use of high-dose chemotherapy with bone marrow transplantation is becoming easier to administer because of improved supportive care techniques and is being increasingly utilized for patients with high-risk primary breast cancer. We report here survey data from 33 medical centers in the United States using this therapeutic approach in 662 patients outside of the cooperative group sponsored randomized clinical trials between 1987 and 1993. Centers provided patient specific data on pretreatment characteristics, therapy and supportive care used, and disease outcome and toxicity data for each patient. Seventy-four percent of the patients were treated by 11 (33{\%}) of the centers; 15 institutions had treated fewer than 10 patients. The median number of lymph nodes involved was 13; the majority of patients (51{\%}) had T2 lesions and 28{\%} of tumors measured more than 5 cm. The most common induction chemotherapy regimens were CAF or AFM, and 72{\%} of patients received one of three transplant preparative regimens. Overall survival at 3 years was 79{\%} (95{\%} CI: 71{\%}-85{\%}) with event-free survival at three years of 69{\%} (95{\%} CI: 61{\%}-76{\%}). Patients with hormone-receptor positive tumors had a event-free (p = 0.02) and overall survival (p = 0.01) that was significantly greater than patients with hormone receptor negative tumors. High-dose chemotherapy with autologous cellular support as consolidation in patients with high-risk primary breast cancer produces event-free and overall survival which appears superior to historical and contemporary data in this setting using standard-dose chemotherapy.",
author = "Peters, {W. P.} and Fay, {J. W.} and Holland, {H. K.} and T. Ahmed and Bolwell, {B. J.} and J. Wolf and L. Damon and G. Long and Lee Schwartzberg and Goldberg, {S. L.} and Friedman, {D. J.} and Lynch, {J. P.} and Weinberger, {B. B.} and Taylor, {R. F.} and E. Stadtmauer and Rifkin, {R. M.} and Broun, {E. R.} and McCarthy, {P. L.} and K. Zamkoff",
year = "1995",
month = "1",
day = "1",
language = "English (US)",
volume = "15",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Autologous bone marrow transplantation in primary breast cancer

T2 - The American experience

AU - Peters, W. P.

AU - Fay, J. W.

AU - Holland, H. K.

AU - Ahmed, T.

AU - Bolwell, B. J.

AU - Wolf, J.

AU - Damon, L.

AU - Long, G.

AU - Schwartzberg, Lee

AU - Goldberg, S. L.

AU - Friedman, D. J.

AU - Lynch, J. P.

AU - Weinberger, B. B.

AU - Taylor, R. F.

AU - Stadtmauer, E.

AU - Rifkin, R. M.

AU - Broun, E. R.

AU - McCarthy, P. L.

AU - Zamkoff, K.

PY - 1995/1/1

Y1 - 1995/1/1

N2 - The use of high-dose chemotherapy with bone marrow transplantation is becoming easier to administer because of improved supportive care techniques and is being increasingly utilized for patients with high-risk primary breast cancer. We report here survey data from 33 medical centers in the United States using this therapeutic approach in 662 patients outside of the cooperative group sponsored randomized clinical trials between 1987 and 1993. Centers provided patient specific data on pretreatment characteristics, therapy and supportive care used, and disease outcome and toxicity data for each patient. Seventy-four percent of the patients were treated by 11 (33%) of the centers; 15 institutions had treated fewer than 10 patients. The median number of lymph nodes involved was 13; the majority of patients (51%) had T2 lesions and 28% of tumors measured more than 5 cm. The most common induction chemotherapy regimens were CAF or AFM, and 72% of patients received one of three transplant preparative regimens. Overall survival at 3 years was 79% (95% CI: 71%-85%) with event-free survival at three years of 69% (95% CI: 61%-76%). Patients with hormone-receptor positive tumors had a event-free (p = 0.02) and overall survival (p = 0.01) that was significantly greater than patients with hormone receptor negative tumors. High-dose chemotherapy with autologous cellular support as consolidation in patients with high-risk primary breast cancer produces event-free and overall survival which appears superior to historical and contemporary data in this setting using standard-dose chemotherapy.

AB - The use of high-dose chemotherapy with bone marrow transplantation is becoming easier to administer because of improved supportive care techniques and is being increasingly utilized for patients with high-risk primary breast cancer. We report here survey data from 33 medical centers in the United States using this therapeutic approach in 662 patients outside of the cooperative group sponsored randomized clinical trials between 1987 and 1993. Centers provided patient specific data on pretreatment characteristics, therapy and supportive care used, and disease outcome and toxicity data for each patient. Seventy-four percent of the patients were treated by 11 (33%) of the centers; 15 institutions had treated fewer than 10 patients. The median number of lymph nodes involved was 13; the majority of patients (51%) had T2 lesions and 28% of tumors measured more than 5 cm. The most common induction chemotherapy regimens were CAF or AFM, and 72% of patients received one of three transplant preparative regimens. Overall survival at 3 years was 79% (95% CI: 71%-85%) with event-free survival at three years of 69% (95% CI: 61%-76%). Patients with hormone-receptor positive tumors had a event-free (p = 0.02) and overall survival (p = 0.01) that was significantly greater than patients with hormone receptor negative tumors. High-dose chemotherapy with autologous cellular support as consolidation in patients with high-risk primary breast cancer produces event-free and overall survival which appears superior to historical and contemporary data in this setting using standard-dose chemotherapy.

UR - http://www.scopus.com/inward/record.url?scp=0029063765&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029063765&partnerID=8YFLogxK

M3 - Article

VL - 15

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - SUPPL. 1

ER -